Cardinal Health (CAH)
(Delayed Data from NYSE)
$113.28 USD
+0.11 (0.10%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $113.27 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.28 USD
+0.11 (0.10%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $113.27 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Zacks News
Is Cardinal Health (CAH) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Company News for Feb 7, 2020
by Zacks Equity Research
Companies in the news are: BMY, CI, NOK, CAH
Cardinal Health (CAH) in Focus: Stock Moves 10.6% Higher
by Zacks Equity Research
Cardinal Health (CAH) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.
Cardinal (CAH) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Cardinal Health (CAH) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
Cardinal Health (CAH) fiscal second-quarter results benefit revenue growth and strong segmental performance. However, contraction in gross margin remains a concern.
Cardinal Health (CAH) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 25.62% and 0.64%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Feb 6 Earnings Roster: BDX, CAH & More
by Zacks Equity Research
Despite the ongoing US-China trade war, increased focus on innovation is likely to have driven performance of medical products players' quarterly performance.
What's in Store for Cardinal Health's (CAH) Q2 Earnings?
by Zacks Equity Research
Cardinal Health (CAH) fiscal second-quarter earnings are likely to reflect better-than-expected performance at Pharmaceutical and Medical segments.
Earnings Preview: Cardinal Health (CAH) Q2 Earnings Expected to Decline
by Zacks Equity Research
Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Cardinal Health (CAH) a Solid Pick for Value Investors?
by Zacks Equity Research
Let's see if Cardinal Health (CAH) stock is a good choice for value-oriented investors right now from multiple angles.
Should Value Investors Buy Cardinal Health (CAH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Cardinal Health (CAH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (CAH) Outperforming Other Medical Stocks This Year?
Should Deep Value ETF (DVP) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for DVP
Here's Why You Should Hold on to Cardinal Health Stock Now
by Zacks Equity Research
Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.
Cardinal (CAH) Upgraded to Buy: Here's Why
by Zacks Equity Research
Cardinal (CAH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why You Should Retain Surmodics (SRDX) Stock for Now
by Zacks Equity Research
Surmodics (SRDX) is gaining from continued strength at Medical Devices unit and persistent efforts to boost R&D functionalities. However, weak performance at Surmodics' IVD unit remains a concern.
Top Ranked Income Stocks to Buy for January 6th
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, January 6th.
Top Ranked Income Stocks to Buy for January 2nd
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, January 2nd.
Here's Why You Should Hold on to Intuitive Surgical for Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base. However, margin contraction remains a concern.
Should Value Investors Buy Cardinal Health (CAH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
CAH or ALGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CAH vs. ALGN: Which Stock Is the Better Value Option?
Should Deep Value ETF (DVP) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DVP
Top Ranked Income Stocks to Buy for December 27th
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, December 27th.
Top Ranked Income Stocks to Buy for December 20th
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, December 20th.
Top Ranked Income Stocks to Buy for December 19th
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, December 19th.